Von-willebrand-factor-top-journals| OMICS International |Brain-Disorders-Therapy

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Von Willebrand Factor Top Journals

The von Willebrand factor (vWF) is an acute stroke response protein involved in platelet aggregation, adhesion, inflammation, and thrombus formation, responses that occur following an ischemic stroke. We hypothesize that administration of an anti-vWF antibody (anti-vWF-Ab) may be used as adjunctive therapy with tissue plasminogen activator (tPA) to promote behavioral improvement following an embolic stroke. The von Willebrand factor (vWF) has emerged as a promising target in stroke therapy because it is involved in the acute phase response following a stroke . vWf is a large multimeric protein that plays a key role in several facets of primary hemostasis . While vWf contains multiple modular internal repeat domains with binding sites for multiple ligands, it is the interaction of the A1 domain with platelet GPIb-α that plays a critical role in two key aspects of the acute phase response; thrombosis under high shear as well as platelet tethering to activated endothelium under low shear. Tissue plasminogen activator (tPA), which results in embolus lysis and cerebral reperfusion remains the only approved thrombolytic therapy for AIS . Extensive clinical research continues to support the use of tPA within an extended therapeutic window of up to 4.5 hours Paul A Lapchak, Synergistic Effect of AJW200, a von Willebrand Factor Neutralizing Antibody with Low Dose (0.9 mg/kg) Thrombolytic Therapy Following Embolic Stroke in Rabbits
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on January, 2021